873225-46-8 Usage
Uses
Used in Pharmaceutical Industry:
IKK 16 is used as an IKK2 inhibitor for the treatment of various immune/inflammatory disorders. Its ability to modulate the immune response makes it a promising candidate for the development of therapeutic agents targeting conditions such as rheumatoid arthritis, inflammatory bowel disease, and other autoimmune disorders.
Biological Activity
ikk-16 (ikk inhibitor vii) is a novel inhibitor of iκb kinase (ikk) with the ic50 values of 0.04μm, 0.2μm and 0.07μm for ikk2, ikk1 and ikk complex, respectively [1].ikk-16 (ikk inhibitor vii) is a 2-benzamido-pyrimidines and selective inhibitor of iκb kinase (ikk). ikk-16 has been reported to effectively inhibit tnfα release into plasma upon lps-challenge in the rat. in addition, ikk-16 has been found to be active at thioglycollate-induced peritonitis model in the mouse. furthermore, ikk-16 has revealed to be an orally bio-available in rats and mice, and have significant in vivo activity in an acute model of cytokine release [1].
references
[1] waelchli r1, bollbuck b, bruns c, buhl t, eder j, feifel r, hersperger r, janser p, revesz l, zerwes hg, schlapbach a.design and preparation of 2-benzamido-pyrimidines as inhibitors of ikk. bioorg med chem lett. 2006 jan 1;16(1):108-12. epub 2005 oct 19.
Check Digit Verification of cas no
The CAS Registry Mumber 873225-46-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,3,2,2 and 5 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 873225-46:
(8*8)+(7*7)+(6*3)+(5*2)+(4*2)+(3*5)+(2*4)+(1*6)=178
178 % 10 = 8
So 873225-46-8 is a valid CAS Registry Number.
873225-46-8Relevant academic research and scientific papers
Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK
Waelchli, Rudolf,Bollbuck, Birgit,Bruns, Christian,Buhl, Thomas,Eder, Joerg,Feifel, Roland,Hersperger, Rene,Janser, Philipp,Revesz, Laszlo,Zerwes, Hans-Guenter,Schlapbach, Achim
, p. 108 - 112 (2007/10/03)
The design, synthesis, and the biological evaluation of 2-benzamido-pyrimidines as novel IKK inhibitors are described. By optimization of the lead compound 3, compounds 16 and 24 are identified as good inhibitors of IKK2 with IC50 values of 40 and 25 nM, respectively. Compound 16 also demonstrated significant in vivo activity in an acute model of cytokine release.
